ARQT vs EMN · rev $235.3M vs P/E 21, rev $9.38B
Arcutis Biotherapeutics Inc (ARQT) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
ARQT currently screens at market cap $1.64B. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the ARQT and EMN stock pages for the full models.
Not investment advice.